Monday, September 8, 2008 - 6:50AM EST

Review Articles

1. Bladder cancer, a two phased disease?

Author
Hoglund M;
Institution
Department of Clinical Genetics, Lund University Hospital, Lund SE-221 81, Sweden. mattias.hoglund@med.lu.se
Journal
Semin Cancer Biol. 2007 Jun;17(3):225-32. Epub 2006 Feb 28.
Abstract URL
Click here to view abstract

2. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors.

Author
Knowles MA;
Institution
Cancer Research UK Clinical Centre, Section of Oncology, Leeds Institute of Molecular Medicine, St James's University Hospital, Beckett Street, Leeds, LS9 7TF, UK. m.a.knowles@leeds.ac.uk
Journal
Future Oncol. 2008 Feb;4(1):71-83.
Abstract URL
Click here to view abstract

3. Biological markers in the diagnosis of recurrent bladder cancer: an overview.

Author
Mohammed A; Khan Z; Zamora I; Bhatti A;
Institution
Urology Unit, North Tees University Hospital Hardwick Road, Stockton on Tees TS19 8PE, UK. aza_bamerny@yahoo.com
Journal
Expert Rev Mol Diagn. 2008 Jan;8(1):63-72.
Abstract URL
Click here to view abstract

4. Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.

Author
Rosenberg JE;
Institution
UCSF Comprehensive Cancer Center, 1600 Divisadero Street, Box 1711, San Francisco, CA 94115, USA. jrosenbe@medicine.ucsf.edu
Journal
Expert Rev Anticancer Ther. 2007 Dec;7(12):1729-36.
Abstract URL
Click here to view abstract

5. The best treatment for high-grade T1 bladder cancer is cystectomy.

Author
Skinner EC;
Institution
Department of Urology, Keck University of Southern California School of Medicine, Los Angeles, CA 90089, USA. skinner@hsc.usc.edu
Journal
Urol Oncol. 2007 Nov-Dec;25(6):523-5.
Abstract URL
Click here to view abstract

6. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.

Author
Hall MC; Chang SS; Dalbagni G; Pruthi RS; Seigne JD; Skinner EC; Wolf JS Jr; Schellhammer PF;
Institution
American Urological Association Education and Research, Inc., USA. Craig.Hall@cornerstonehealthcare.com
Journal
J Urol. 2007 Dec;178(6):2314-30.

7. Pathological variants of invasive bladder cancer according to their suggested clinical significance.

Author
Lopez-Beltran A; Requena MJ; Cheng L; Montironi R;
Institution
Department of Pathology, Reina Sofia University Hospital and Cordoba University Medical School, Cordoba, Spain. em1lobea@uco.es
Journal
BJU Int. 2008 Feb;101(3):275-81. Epub 2007 Nov 6.
Abstract URL
Click here to view abstract

8. Surgery insight: advantages and disadvantages of laparoscopic radical cystectomy to treat invasive bladder cancer.

Author
Puppo P; Introini C; Naselli A;
Institution
Largo Rosanna Benzi 10, National Institute for Cancer Research, Genoa, Italy. paolo.puppo@auro.it
Journal
Nat Clin Pract Urol. 2007 Jul;4(7):387-94.
Abstract URL
Click here to view abstract

9. Muscle-invasive urothelial carcinoma of the bladder.

Author
Malkowicz SB; van Poppel H; Mickisch G; Pansadoro V; Thuroff J; Soloway MS; Chang S; Benson M; Fukui I;
Institution
Department of Urology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
Journal
Urology. 2007 Jan;69(1 Suppl):3-16.
Abstract URL
Click here to view abstract

10. An updated review of the literature: risk factors for bladder cancer with focus on occupational exposures.

Author
Olfert SM; Felknor SA; Delclos GL;
Institution
University of Texas School of Public Health at Houston, Southwest Center for Occupational and Environmental Health, Houston, TX 77030, USA.
Journal
South Med J. 2006 Nov;99(11):1256-63.
Abstract URL
Click here to view abstract
Pages: 1 2 3 4 5 6